IDEAYA Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IDYA research report →
Companywww.ideayabio.com
IDEAYA Biosciences, Inc. , a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.
- CEO
- Yujiro S. Hata
- IPO
- 2019
- Employees
- 131
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $2.61B
- P/E
- -18.78
- P/S
- 11.56
- P/B
- 2.81
- EV/EBITDA
- -13.84
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.49%
- Op Margin
- -81.44%
- Net Margin
- -62.17%
- ROE
- -13.96%
- ROIC
- -19.00%
Growth & Income
- Revenue
- $218.71M · 3024.43%
- Net Income
- $-113,698,000 · 58.58%
- EPS
- $-1.28 · 61.90%
- Op Income
- $-159,313,000
- FCF YoY
- 70.78%
Performance & Tape
- 52W High
- $39.28
- 52W Low
- $18.25
- 50D MA
- $31.04
- 200D MA
- $30.69
- Beta
- -0.04
- Avg Volume
- 1.18M
Get TickerSpark's AI analysis on IDYA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 2, 26 | Stein Jeffrey | buy | 50,000 |
| Jan 30, 26 | Bleharski Joshua | other | 170,000 |
| Jan 30, 26 | WHITE MICHAEL ANTHONY | other | 190,000 |
| Jan 30, 26 | Beaupre Darrin | other | 175,000 |
| Jan 30, 26 | DORMAN STUART | other | 155,000 |
| Jan 30, 26 | Hata Yujiro S | other | 600,000 |
| Jan 30, 26 | Snyder Douglas B. | other | 130,000 |
| Nov 28, 25 | Snyder Douglas B. | other | 1,041 |
| May 30, 25 | Snyder Douglas B. | other | 1,039 |
| Jan 30, 26 | Ruiz Briseno Andres | other | 80,000 |
Our IDYA Coverage
We haven't published any research on IDYA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IDYA Report →